Navigation Links
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:10/7/2008

and dose response of linaclotide in patients with IBS-C. The primary efficacy endpoint was change from baseline in CSBM frequency. The study evaluated the effects of 75, 150, 300 or 600 ug linaclotide or placebo administered orally once daily to adults meeting modified Rome II criteria for IBS-C. Participants underwent two-week-baseline, 12-week-treatment, and two-week-post-treatment evaluations with daily assessments of bowel habits and symptom severity, and weekly global assessments using an interactive voice response system. During the baseline period patients had to demonstrate <3 CSBM/week and mean daily abdominal pain of at least mild severity. Treatment effects in the intent-to-treat population were estimated using an analysis of covariance and the Cochran-Mantel Haenszel test.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, CC, and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition- throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
2. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
3. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
4. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
5. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
6. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Gary A. Puckrein , PhD, ... Forum (NMQF), today will present an award to ... Research and Manufacturers of America (PhRMA), for his ... behalf of PhRMA, and in conjunction with NMQF, Castellani ... awareness, start conversations, and increase diversity in clinical trials, ...
(Date:4/21/2015)... -- The North American dermatology diagnostic devices market is ... 2014 to 2019. Although mature markets (the U.S. and ... the dermatology diagnostic devices market, Mexico ... of 9.8% during the forecast period. The growth of ... such as rising incidences of skin disorders, increasing demand ...
(Date:4/21/2015)... April 21, 2015 Softheon, Inc., ... integration and business operation, has confirmed its status ... Centers of Medicare & Medicaid Services (CMS).  Under ... with access to the Federal Data Hub to ... into qualified health insurance plans. ...
Breaking Medicine Technology:National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 3North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 2North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 3Softheon Confirms Web Broker Entity (WBE) Status with the Centers of Medicare & Medicaid Services (CMS) 2
(Date:4/21/2015)... 2015 On April 8th, 2015, Choices ... at the world famous Avalon Hollywood. Organized by Debbie ... in TV and film, the EcoLuxe Lounge is a ... awards ceremonies and festivals throughout the year. A gathering ... and socially conscious products and services, this daylong event ...
(Date:4/21/2015)... Colmar, PA (PRWEB) April 21, 2015 ... Ichthyosis & Related Skin Types, Inc.® (FIRST) will publish ... ichthyosis. The campaign will run throughout the month of ... Voice. It Matters to Someone." The positioning was ... about this rare skin disorder and to help support ...
(Date:4/21/2015)... 21, 2015 Approximately 75 million Americans ... U.S. Environmental Protection Agency (EPA). On top of this, ... smoke increase the level of toxins found in the ... these harmful toxins is to increase consumption of broccoli. ... highest level of glucoraphanin – a long-lasting antioxidant – ...
(Date:4/21/2015)... 21, 2015 As a provider of ... found that their rehabilitation strategy, which involves various treatment ... relapses. In an effort to offer hope and encouragement ... their lives, Best Drug Rehabilitation has featured a series ... many successful graduates of their recovery program. , ...
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
Breaking Medicine News(10 mins):Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 3Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2
... Inc. and TPABenefits, Inc.,of San Antonio, TX announced ... INETICO system and the TPABenefits Web Portal. This ... Pre-Certification,and Wellness data source and allows Payors, TPA,s, ... Case Notes on the,TPABenefits Web Portal., The ...
... Calif., May 8 IRIDEX,Corporation (Nasdaq: IRIX ) ... financial results after the market closes on Tuesday, May ... host a conference,call with the investment community at 5:00 ... the results of the quarter and other business,developments., ...
... Viruses are masters of deception, duping their host,s cells ... has found that human cytomegalovirus (HCMV) can mimic a ... disrupting a cell,s primary anti-cancer mechanism. , Writing in ... University of Wisconsin-Madison and Harvard Medical School report that ...
... disease, osteoarthritis (OA) is the leading cause of disability in ... OA most often strikes the knee, particularly the inner aspect ... this vulnerable joint compartment is the knee adduction moment, an ... increase in the peak knee adduction moment is associated with ...
... More than 8,700 babies born each year in Washington to ... is,one of the best things a woman can do to ... time for Mother,s Day on May 11, the state,Department of ... Line,to provide pregnant women with more help when they,re ready ...
... MADISON, Wis., May 8 Let,s face it,Americans ... prove,positive, like when it promotes greater awareness and ... of cancer, lung cancer,causes almost twice as many ... today launched a national, multi-media public service,announcement (PSA) ...
Cached Medicine News:Health News:INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution 2Health News:Virus mimics human protein to hijack cell division machinery 2Health News:Cane use may reduce risk of knee osteoarthritis progression 2Health News:Cane use may reduce risk of knee osteoarthritis progression 3Health News:Tobacco Quit Line Expands Services for Pregnant Women Who Smoke 2Health News:National Lung Cancer Partnership Launches Campaign to Raise Lung Cancer Awareness Among Women 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: